Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

Maternal diet doesn't affect baby's food allergy risk

Higher maternal consumption of egg and peanut during pregnancy and breastfeeding does not protect...

Overuse of inhalers can increase heart attack risk

Overuse of reliever inhalers is associated with higher risks of developing and dying from...

Unhealthy Western diet could accelerate cognitive decline

An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...

Content from other channels on our network

Fremantle Seaweed acquires onshore seaweed technology

Emergency crises hub launched for Asia–Pacific

AWA celebrates National Water Week 2026

Co-digesting textile and food waste could create renewable methane

ACCC guidance on emissions claims to consumers released

Better questions, clearer choices: putting the person at the centre of continence support

A Day in the Life of a rural generalist anaesthetist and men's mental health advocate

Government to commission aged care assessment tool review

Services commence today at Flinders Street Health

Burnout in health care isn't an 80/20 problem: why a more balanced view is needed and what it means for you and your workplace

Solving the static charge dilemma for less clumpy shakes

A three-level strategy for preventing moisture 'drift' in food production

Digital Memosens technology for pH measurments

Bottling line for resealable aluminium beverages

Allied Pinnacle invests $10m in Sydney manufacturing capacity